Truvestments Capital’s Akari Therapeutics AKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5 | Hold |
1
| – | – | ﹤0.01% | 1173 |
|
|
2025
Q4 | $14 | Hold |
1
| – | – | ﹤0.01% | 1025 |
|
|
2025
Q3 | $51 | Hold |
1
| – | – | ﹤0.01% | 1006 |
|
|
2025
Q2 | $59 | Hold |
1
| – | – | ﹤0.01% | 936 |
|
|
2025
Q1 | $62 | Hold |
1
| – | – | ﹤0.01% | 1007 |
|
|
2024
Q4 | $61 | Hold |
1
| – | – | ﹤0.01% | 996 |
|
|
2024
Q3 | $148 | Buy |
+1
| New | +$139 | ﹤0.01% | 906 |
|
|
2024
Q2 | – | Sell |
-1
| Closed | -$93 | – | 237 |
|
|
2024
Q1 | $93 | Hold |
1
| – | – | ﹤0.01% | 713 |
|
|
2023
Q4 | $156 | Hold |
1
| – | – | ﹤0.01% | 774 |
|
|
2023
Q3 | $198 | Hold |
1
| – | – | ﹤0.01% | 664 |
|
|
2023
Q2 | $171 | Hold |
1
| – | – | ﹤0.01% | 677 |
|
|
2023
Q1 | $183 | Hold |
1
| – | – | ﹤0.01% | 654 |
|
|
2022
Q4 | $472 | Sell |
1
-1
| -50% | -$414 | ﹤0.01% | 870 |
|
|
2022
Q3 | $1K | Hold |
2
| – | – | ﹤0.01% | 579 |
|
|
2022
Q2 | $2K | Buy |
+2
| New | +$1.77K | ﹤0.01% | 548 |
|
|
2022
Q1 | – | Sell |
-2
| Closed | -$2K | – | 193 |
|
|
2021
Q4 | $2K | Hold |
2
| – | – | ﹤0.01% | 543 |
|
|
2021
Q3 | $3K | Hold |
2
| – | – | ﹤0.01% | 497 |
|
|
2021
Q2 | $3K | Hold |
2
| – | – | ﹤0.01% | 503 |
|
|
2021
Q1 | $4K | Sell |
2
-1
| -33% | -$2.27K | ﹤0.01% | 533 |
|
|
2020
Q4 | $3K | Buy |
+3
| New | +$4.16K | ﹤0.01% | 521 |
|
|
2020
Q3 | – | Sell |
-3
| Closed | -$4K | – | 320 |
|
|
2020
Q2 | $4K | Buy |
+3
| New | +$4.57K | ﹤0.01% | 467 |
|
|
2019
Q4 | – | Sell |
-5
| Closed | -$6K | – | 153 |
|
|
2019
Q3 | $6K | Hold |
5
| – | – | ﹤0.01% | 546 |
|
|
2019
Q2 | $8K | Hold |
5
| – | – | 0.01% | 548 |
|
|
2019
Q1 | $14K | Buy |
+5
| New | +$9.54K | 0.01% | 458 |
|
|
2018
Q3 | $11K | Buy |
+5
| New | +$8.07K | 0.01% | 612 |
|
Other funds holding AKTX
AC
CAM
IA
SS
Truvestments Capital's AKTX Position: Q1 2026 in Review
Truvestments Capital held its Akari Therapeutics (AKTX) position steady in Q1 2026 at 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1173.
Truvestments Capital first reported a position in AKTX in Q3 2018 and has held it in 25 quarters since. The position peaked at $14K in Q1 2019. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.
- Truvestments Capital held 1 share of Akari Therapeutics worth $5 as of Q1 2026.
- Truvestments Capital left its Akari Therapeutics share count unchanged in Q1 2026.
- Akari Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1173 holding.
- Truvestments Capital first reported a position in Akari Therapeutics in Q3 2018 and has held it in 25 quarters since.
- Truvestments Capital's Akari Therapeutics position peaked at $14K in Q1 2019.
- 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.
Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.